The Concept Life Sciences Groups Expands Its Services To The U.S.
The Concept Life Sciences Group, a group created following the acquisition of Peakdale Molecular Limited, Scientific Analysis Laboratories Limited and Resource & Environmental Consultants Limited, has launched its services in the US. The integrated group, which further expanded following the acquisition of CXR Biosciences and Agenda1 Analytical Services in 2015, offers a comprehensive range of services to clients in the pharmaceutical, biotech, agrochemical, petrochemical, chemical, food, environmental and consumer industries.
The US team will be led by Heidi Schulze, Business Development Director, North America, who will be driving the sales efforts on the East coast and coordinating with the West Coast business team. Heidi began her career in the research laboratories at Ayerst Pharmaceuticals and then combined her chemistry knowledge with her graduate training in electrical engineering and computer programming at Zymark Corporation, a pioneer in laboratory sample preparation automation. Since then Heidi has continued her career at a number of well-known companies including Hewlett Packard, Shimadzu, Ciphergen Biosystems and BioClinica. Most recently Heidi was with XenoBiotic Laboratories, a subsidiary of WuXi AppTec, Inc.
The combination of expertise housed within the Concept Life Sciences Group is unique in the market and enables companies to access a broad range of services with one point of contact. With companies across a number of sectors facing challenges to achieve and maintain profitable growth, outsourcing remains a significant opportunity. By forming strategic relationships with partners such as Concept Life Sciences, companies can both spread commercial risk and focus on their core competencies whilst accessing specialised expertise and benefitting from the resulting cost and time to market advantages.
Michael Fort continued: “The way we have structured our business enables us to provide project support as efficiently as end-to-end support to our clients. We can work with specific functional areas or work alongside a client from first concept through to the clinic door. This approach has been of significant interest to customers within the UK but has also attracted the attention of customers in the US. We have tested our ability to offer our services here and, after a successful pilot, have now officially launched our US offering. ”
Over 70 per cent of the Concept Life Sciences team who work in the Discovery & Development division are PhD scientists experienced in complex chemistry, pharmacology and pathways analysis working alongside their biology colleagues, who are experts in investigative and mechanistic toxicology, exploratory and discovery toxicology, PK and metabolic and dermal absorption. By ensuring Concept Life Science’s scientific teams work in step with each other, clients are well placed to benefit from an accelerated testing cycle.
Additionally, through their analytics division, Concept Life Sciences offers over 35 different analytical techniques including specialist characterisation instrumentation, chromatography and formulation/salt/polymorph screening to complete the Design, Make, Test cycle.
Michael Fort concluded: “The rationale for the creation of the Concept Life Sciences Group was the recognition that there is a need in the market for a services organisation that has a proven track record in discovery science, problem solving and collaboration. We have built an organisation that delivers one of the widest range of analytical services available in Europe and are now keen to offer those services further afield.”
The US team will be led by Heidi Schulze, Business Development Director, North America, who will be driving the sales efforts on the East coast and coordinating with the West Coast business team. Heidi began her career in the research laboratories at Ayerst Pharmaceuticals and then combined her chemistry knowledge with her graduate training in electrical engineering and computer programming at Zymark Corporation, a pioneer in laboratory sample preparation automation. Since then Heidi has continued her career at a number of well-known companies including Hewlett Packard, Shimadzu, Ciphergen Biosystems and BioClinica. Most recently Heidi was with XenoBiotic Laboratories, a subsidiary of WuXi AppTec, Inc.
The combination of expertise housed within the Concept Life Sciences Group is unique in the market and enables companies to access a broad range of services with one point of contact. With companies across a number of sectors facing challenges to achieve and maintain profitable growth, outsourcing remains a significant opportunity. By forming strategic relationships with partners such as Concept Life Sciences, companies can both spread commercial risk and focus on their core competencies whilst accessing specialised expertise and benefitting from the resulting cost and time to market advantages.
Michael Fort continued: “The way we have structured our business enables us to provide project support as efficiently as end-to-end support to our clients. We can work with specific functional areas or work alongside a client from first concept through to the clinic door. This approach has been of significant interest to customers within the UK but has also attracted the attention of customers in the US. We have tested our ability to offer our services here and, after a successful pilot, have now officially launched our US offering. ”
Over 70 per cent of the Concept Life Sciences team who work in the Discovery & Development division are PhD scientists experienced in complex chemistry, pharmacology and pathways analysis working alongside their biology colleagues, who are experts in investigative and mechanistic toxicology, exploratory and discovery toxicology, PK and metabolic and dermal absorption. By ensuring Concept Life Science’s scientific teams work in step with each other, clients are well placed to benefit from an accelerated testing cycle.
Additionally, through their analytics division, Concept Life Sciences offers over 35 different analytical techniques including specialist characterisation instrumentation, chromatography and formulation/salt/polymorph screening to complete the Design, Make, Test cycle.
Michael Fort concluded: “The rationale for the creation of the Concept Life Sciences Group was the recognition that there is a need in the market for a services organisation that has a proven track record in discovery science, problem solving and collaboration. We have built an organisation that delivers one of the widest range of analytical services available in Europe and are now keen to offer those services further afield.”